HRS4R
Vull donar

PILAR BARRETINA GINESTA

Firma
PILAR BARRETINA-GINESTA
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1

Publicacions

0

SEOM-GEICO clinical guidelines on endometrial cancer (2021).

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 625-634 dx.doi.org/10.1007/s12094-022-02799-7
0

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.

Journal for ImmunoTherapy of Cancer, 2021, 9 dx.doi.org/10.1136/jitc-2021-003645
0

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.

FUTURE ONCOLOGY, 2021, 17, 3781-3785 dx.doi.org/10.2217/fon-2021-0598
0

Management of advanced ovarian cancer in Spain: an expert Delphi consensus.

JOURNAL OF OVARIAN RESEARCH, 2021, 14, 72-72 dx.doi.org/10.1186/s13048-021-00816-x
0

SEOM clinical guideline in ovarian cancer (2020).

CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23, 961-968 dx.doi.org/10.1007/s12094-020-02545-x
0

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.

Cancer Management and Research, 2020, 12, 10251-10260 dx.doi.org/10.2147/CMAR.S270392
0

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO).

Gynecologic Oncology Reports, 2020, 33, 100594-100594 dx.doi.org/10.1016/j.gore.2020.100594
0

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors.

EMBO MOLECULAR MEDICINE, 2020, 12 dx.doi.org/10.15252/emmm.201911217

Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dienstmann R, Oaknin A

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

GYNECOLOGIC ONCOLOGY, 2019, 152, 270-277 dx.doi.org/10.1016/j.ygyno.2018.11.036
0

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381, 2391-2402 dx.doi.org/10.1056/NEJMoa1910962

Formulari de contacte

Coneix l’IDIBGI!

menu